Highlights Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-17 pm EDT			5-day change	1st Jan Change
11.2 ^USD	-5.08%		+0.45%	-38.16%

Jun. 13	Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors	CI
May. 14	Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	May. 14	MT
Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial	May. 14	MT
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis	May. 14	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	Mar. 12	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	Feb. 04	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	23-09-26	CI
Earnings Flash (PLRX) PLIANT THERAPEUTICS Reports Q2 Revenue $248,000	23-08-09	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-09	CI
Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress	23-06-23	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures	23-04-30	CI
Pliant Therapeutics Starts Bexotegrast Enrollment at Higher Dose in Primary Sclerosing Cholangitis Trial	23-03-13	MT
Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis	23-03-13	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Pliant Therapeutics, Inc. Announces 24-Week Data from the 320 mg Dose Group of the INTEGRIS-IPF Phase 2a Trial in Patients with IPF is Expected in the Second Quarter of 2023	23-03-09	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Earnings Flash (PLRX) PLIANT THERAPEUTICS Reports Q4 Revenue $1.97M	23-03-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Highlights

Filters